NAKI Therapeutics
Our core technology is surrounding Chimeric Antigen Receptor (CAR)-Natural Killer (NK) immunotherapy with ground-breaking allogeneic or ‘off-the-shelf’ expansion technology and a ‘first-in-class’ solid tumor molecular target-CD147.
| Date | Investors | Amount | Round |
|---|---|---|---|
* | N/A | - | |
| Total Funding | 000k | ||
Related Content
NAKI Therapeutics is a pioneering biopharmaceutical company focused on developing advanced cell therapies for cancer treatment. Specializing in Chimeric Antigen Receptor (CAR) Natural Killer (NK) cell immunotherapy, NAKI Therapeutics re-engineers NK cells to target the CD147 cancer cell surface marker, enhancing the effectiveness and safety of cancer treatments compared to existing options. The company's proprietary methods enable the rapid and high-purity expansion of potent NK and CAR NK cells, making the therapy scalable and cost-effective. NAKI Therapeutics primarily targets hepatocellular carcinoma (HCC), a severe form of liver cancer with limited effective treatments. The company serves the biopharmaceutical market, focusing on research institutions and healthcare providers. NAKI Therapeutics generates revenue through the development and commercialization of its innovative cell therapies.
Keywords: CAR NK cells, CD147, immunotherapy, hepatocellular carcinoma, biopharmaceutical, cell expansion, cancer treatment, solid tumors, scalable therapy, proprietary technology.